A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Recombinant Proteins, HIV Envelope Protein gp160, AIDS Vaccines, Anti-HIV Agents, Treatment Experienced, HIV Therapeutic Vaccine
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are HIV-positive. Have a viral load (amount of HIV in the blood) of less than 50 copies/ml. Have been taking anti-HIV drugs for at least 2 years. Are already participating in ongoing clinical trials at the Aaron Diamond AIDS Research Center. Are at least 19 years old. Practice abstinence or use 2 barrier methods of birth control, both men and women who are able to have children. Exclusion Criteria Patients will not be eligible for this study if they: Have HIV infection that is spreading through the body even though they are taking anti-HIV drugs. Are breast-feeding. Are pregnant. Are allergic to eggs and/or neomycin. Show evidence of poor immune responses.
Sites / Locations
- Aaron Diamond AIDS Res Ctr